Subscribe
Subscribe

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

New laser-based medical device revolutionizes cardiovascular disease diagnosis

A microbiome solution for type 1 diabetes?

Avoiding the pitfalls of clinical development as a biotech

argenx signs billion-dollar deal with Janssen

A Personal Translation of Microbiome Futures

Battling antibiotic resistance: a new protein powered solution

IPBES to Launch Global Assessment Report on Biodiversity and Ecosystem Services

19 November 2018 - Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) to Launch First Global Assessment Report on Biodiversity and Ecosystem Services Since 2005

Why start-ups can become mega companies in the pharma sector

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle

14 Nov 2018 - Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC), containing 15 mg Estetrol (E4)/ 3 mg drospirenone (DRSP). Top line data remain on track to be reported in Q1 2019.

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

New laser-based medical device revolutionizes cardiovascular disease diagnosis

A microbiome solution for type 1 diabetes?

Avoiding the pitfalls of clinical development as a biotech

argenx signs billion-dollar deal with Janssen

A Personal Translation of Microbiome Futures

Battling antibiotic resistance: a new protein powered solution

IPBES to Launch Global Assessment Report on Biodiversity and Ecosystem Services

19 November 2018 - Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) to Launch First Global Assessment Report on Biodiversity and Ecosystem Services Since 2005

Why start-ups can become mega companies in the pharma sector

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle

14 Nov 2018 - Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC), containing 15 mg Estetrol (E4)/ 3 mg drospirenone (DRSP). Top line data remain on track to be reported in Q1 2019.